Drug prices are plunging—but who really deserves the credit?
Left says
- •The Inflation Reduction Act's Medicare negotiation provisions, a Biden-era policy, took effect in January and cut negotiated prices as much as 79% below list prices for 10 costly drugs, a factor health economists say deserves significant credit.
- •A prominent health economist argues that if policy credit is to be assigned, it belongs to the IRA, while broader market forces like generic and biosimilar competition are also major drivers unrelated to Trump's actions.
- •The White House shared a Washington Post headline touting the price drop while omitting that the article's cited experts actually credited Biden-era policy, raising concerns about selective framing.
- •Falling aggregate prices don't necessarily translate into relief for ordinary people, since six in 10 Americans remain worried about affording medications and four in 10 have skipped doses due to cost.
Right says
- •Trump's Most Favored Nation deals and the TrumpRx platform have driven direct, measurable savings, including GLP-1 drugs dropping from over $1,000 a month to starting at $149.
- •TrumpRx has already generated $700 million in patient savings, and the VA has locked in more than $10 billion in pharmaceutical savings this fiscal year with hundreds of billions projected long-term.
- •The administration argues the IRA's negotiated prices didn't meaningfully beat existing insurer discounts, calling credit given to that law unfounded, and instead points to direct deals with drugmakers as the real cause.
- •This marks the first time prescription prices have actually fallen under a president after decades of increases that had U.S. consumers effectively subsidizing lower drug prices paid by other countries.
Common Take
High Consensus- Prescription drug prices fell 3.1% over the past year, the steepest annual decline since 1963.
- Multiple factors are likely contributing simultaneously, including federal policy, drug company deals, and generic/biosimilar market competition.
- The prescription drug price index reflects what pharmacies are paid by insurers and Medicare, not necessarily what individual consumers pay out of pocket.
- Both sides agree that lower aggregate prices are a positive development worth publicizing, even as they disagree on which policies caused it.
The Arguments
Left argues
Health economists cited by both Axios and the AP say that if any policy deserves credit for falling drug prices, it's the IRA's Medicare negotiation provisions, which cut prices as much as 79% below list on 10 costly drugs starting in January—well before Trump's most-favored-nation deals could plausibly show up in the data.
Right counters
The White House counters that IRA-negotiated prices largely mirrored discounts insurers already secured through rebates, meaning the law's real-world impact on net prices was marginal, whereas Trump's MFN deals and TrumpRx produced direct, verifiable cash-price cuts like the GLP-1 drop from $1,000+ to $149.
Right argues
TrumpRx has already delivered $700 million in documented patient savings, the VA has locked in $10 billion in pharmaceutical savings this fiscal year, and this marks the first time under any president that prescription prices have actually fallen rather than merely slowed their rise.
Left counters
Axios's own reporting notes TrumpRx 'likely only accounts for part of the decline' and often just makes existing discounts easier to find rather than creating new ones, while broader market forces—generic and biosimilar competition entering after patent expirations—were already driving prices down independent of any Trump policy.
Left argues
The White House shared a Washington Post headline touting the price drop while omitting that the article's own cited experts attributed the decline to Biden-era policy, a selective framing that raises legitimate concerns about the administration misrepresenting its own source material.
Right counters
Regardless of which article headline was shared, the underlying CPI data showing the steepest drop since 1963 is undisputed, and the administration argues it's fair to highlight favorable data points—just as any administration touts good news—rather than debate media framing choices.
Right argues
Decades of data show U.S. prescription drug prices rose 5.5 times since 1985, roughly three times faster than overall inflation, effectively subsidizing lower prices paid by other countries—and Trump's direct deals with drugmakers are the first policy mechanism to reverse that trend in real time.
Left counters
Even if the trend has reversed, falling aggregate prices don't necessarily translate into relief for ordinary people: six in 10 Americans remain worried about affording medications and four in 10 have skipped doses due to cost, since consumers respond to their copay, not the underlying list price the CPI measures.
Left argues
The prescription drug CPI measures what pharmacies are paid by insurers and Medicare, not what consumers pay out of pocket, and doesn't capture manufacturer rebates paid after the transaction—meaning the touted 3.1% drop is a technical statistical measure that may not reflect real patient experience.
Right counters
Whatever the CPI's limitations, TrumpRx's $700 million in savings and the VA's $10 billion in pharmaceutical savings are concrete, measurable dollar figures tied directly to negotiated deals, not just an abstract index shift open to competing interpretations.
Challenge Questions
These questions target genuine internal contradictions — meant to provoke honest reflection.
Right asks Left
“If the IRA's Medicare negotiations are the primary driver of falling prices, why do six in 10 Americans still report being worried about affording medications and four in 10 report skipping doses—shouldn't a policy credited with such dramatic effect show up more clearly in patient experience?”
Left asks Right
“If TrumpRx and the MFN deals are the real cause of falling prices, why does the administration simultaneously argue that IRA-negotiated prices didn't beat existing insurer discounts, when both are competing to explain the same CPI decline that began before many of Trump's deals took effect?”
Outlier Report
Left Fringe
Progressive figures like Bernie Sanders and health policy advocates at groups like Public Citizen who argue the IRA didn't go far enough and that any Trump-era savings are insufficient or cosmetic represent maybe 15-20% of the left, pushing a more skeptical 'nothing has really improved' framing.
Right Fringe
MAGA-aligned commentators and figures like Sean Hannity or some White House communications staff who present Trump's actions as singularly responsible with no caveats, dismissing any IRA contribution entirely, represent roughly 20-25% of the right and amplify the most triumphalist framing.
Noise Assessment
High noise ratio — this is largely an inside-the-Beltway credit-claiming battle amplified by dueling White House social media posts and think-tank economists; most ordinary Americans are likely unaware of the specific policy attribution debate and simply react to whether their own drug costs feel lower.
Sources (5)
The White House flooded social media on Saturday with an image of Donald Trump showing off the recent Washington Post headline "Prescription drug prices record sharpest drop in more than 60 years", but failed to mention that experts cited in the article actually attributed the price drop to Joe Biden, not Trump.
The White House is crowing over a 3.1% dip in prescription prices as evidence that President Trump's pressure on drug companies is working — claiming Monday that it is the "steepest drop since 1963."
<div>Data: Bureau of Labor Statistics; Chart: Courtenay Brown/Axios</div><p>America is experiencing its biggest prescription drug price deflation in generations. </p><p><strong>Why it matters: </strong>By one important measure, there is a striking reversal underway for one of health care's most stubbornly expensive necessities amid a major Washington push to lower drug costs.</p><hr /><p><strong>By the numbers: </strong>Prescription drug prices fell 0.8% in July and are down 3.1% from a year ago — the steepest annual decline in more than six decades, according to the <a href="https://www.axios.com/2026/08/12/inflation-cpi-fed-middle-east" target="_blank">recent Consumer Price Index</a>. </p><ul><li>Prices haven't risen in any month this year, an unusually persistent stretch of flat or falling drug prices.</li><li>The downward trend comes as costs for hospital and physician services continue to rise.</li></ul><p><strong>The intrigue:</strong> Trump administration officials are taking a victory lap for the price drop, although <a href="https://www.axios.com/2026/02/06/trump-trumprx-drug-prices-site-live-online" target="_blank">TrumpRx</a> — the administration's website connecting patients with discounted cash prices for certain drugs — likely only accounts for part of the decline.</p><ul><li>Eli Lilly and Novo Nordisk also struck deals with the administration that cut cash prices for blockbuster GLP-1 drugs and expanded Medicare access.</li><li>Those cuts may have added to broader downward pressure on drug prices, though other forces were already at work.</li></ul><p><strong>Another potential factor:</strong> Medicare negotiations established under the Inflation Reduction Act took effect in January for 10 of the program's costliest drugs, with negotiated prices as much as <a href="https://www.axios.com/2024/08/15/medicare-drug-price-negotiations-savings-announced" target="_blank">79% below their list prices</a>.</p><p><strong>Zoom in:</strong> Changes in what Medicare pays pharmacies can show up in the prescription drug CPI.</p><ul><li>The government tracks the prices that pharmacies receive from patients and insurers, including Medicare, not just what consumers pay out of pocket.</li><li>Manufacturer rebates paid after the transaction are not captured in the index, the Bureau of Labor Statistics told Axios.</li></ul><p><strong>What they're saying: </strong>Geoffrey Joyce, a USC health economist, said that TrumpRx makes discounts easier to find but often points consumers to prices that already exist.</p><ul><li>"If you were going to give policy credit, you'd have to say the IRA," Joyce said. Still, he added, much of the decline is being driven by market forces.</li></ul><p><strong>The big picture: </strong>As blockbuster drugs lose patent protection, cheaper generics enter the market, a shift the government's inflation gauge is designed to capture.</p><ul><li>Heated competition in the market for GLP-1 drugs is pushing down cash-pay prices.</li></ul><p><strong>The other side:</strong> White House spokesperson Kush Desai called attributing the decline to the IRA "idiotic and unfounded," arguing that its negotiated prices failed to deliver meaningful savings beyond existing insurer discounts.</p><ul><li>Desai pointed instead to Trump's most-favored-nation deals, aimed at aligning U.S. drug prices with lower prices overseas, and discounts available through TrumpRx.</li></ul><p><strong>What we're watching: </strong>Falling prices in the aggregate do not necessarily translate into relief for consumers, given the complexity of drug pricing and payments. </p><ul><li>Six in 10 Americans <a href="https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/" target="_blank">this spring said</a> they were worried about affording their medications, according to KFF — the largest share since the group began tracking the question in 2018.</li><li>Four in 10 said that in the past year they hadn't taken medication as prescribed because of cost.</li><li>"People don't care about what the true cost of the drug is," Joyce said. "They just say, 'What's my copay?' or 'What's my cost sharing at the pharmacy counter?'"</li></ul><p><em>Caitlin Owens and Adriel Bettelheim contributed reporting.</em></p>
Prescription prices are down 3.9% since Trump took office and have declined every month of 2026. Nonprescription drugs fell 2.4% and medical-care commodities 2.7% over the past year.
New federal data that shows U.S. prescription drug prices fell 0.8% in July and are down 3.1% from a year ago, the steepest year-over-year drop since 1963.